Cardio Diagnostics (CDIO)

• Market cap: $19M
• 1 day: 10.70%
• 5 days: -15.65%
• 1 month: -13.27%
• 3 months: -58.20%
• 6 months: 76.05%
• Year to date: -58.20%
• 1 year: -73.72%
• 5 years: -96.28%
• 10 years: -96.28%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Employees: 9

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

530% more capital invested

Capital invested by funds: $374K [Q3] → $2.35M (+$1.98M) [Q4]

53% more funds holding

Funds holding: 15 [Q3] → 23 (+8) [Q4]

0.13% less ownership

Funds ownership: 6.48% [Q3] → 6.36% (-0.13%) [Q4]